
    
      The study was prematurely discontinued on 14 September 2011 due to no significant
      pharmacological effects (safety/PD/efficacy) through 25 mg/kg cohort, the T1/2 based on VEGF
      binding was shorter than expected and the current and/or higher doses were not considered
      feasible for further development. There were no safety concerns associated with the decision
      to terminate the program/study.
    
  